

January 18, 2022

To: Maryland House of Representatives  
Health and Government Operations Committee  
Delegate Shane E. Pendergrass, Chair, and Members of the Committee  
Room 241, House Office Building  
Annapolis, Maryland 21401

Dear Chair Pendergrass and Members of the Committee,

AANP appreciates the opportunity to submit written testimony **in support of the proposed legislation, [House Bill 0049, An Act Concerning Public Health – Emergency and Allergy Treatment Program – Nurse Practitioners](#)**, as introduced by Delegate Johnson and currently under consideration by the [Health and Government Operations Committee](#) during the public comment period available for the hearing scheduled for Thursday, January 13, 2022.

The American Association of Nurse Practitioners® (AANP) is the largest professional membership organization for nurse practitioners (NPs) of all specialties and represents the interests of the more than 325,000 licensed NPs in the United States. As the voice for NPs, AANP is invested on behalf of our membership and their patients in any legislation that may impact policy and health care delivery.

On behalf of our more than one thousand eight-hundred Maryland Nurse Practitioner members in the state, who represent nearly one-third of Maryland's entire NP workforce, AANP supports this legislation.

- Maryland law currently authorizes NPs to prescribe, order and administer this medication. House Bill 0049 would not change or expand scope of practice for NPs.
- If enacted as introduced, House Bill 0049 would update the list of providers who are specifically authorized to administer this medication at youth camps under existing state law regulating these camps.
- Given the remote location of camps and the potentially lifesaving administration of Epinephrine, this necessary update will make it easier for youth to get timely care when they need it.
- The majority of states that separately regulate medication administration for youth camps include NPs in the list of providers authorized to administer this medication.

On behalf of the American Association of Nurse Practitioners and our Maryland membership, we ask for your vote in support of House Bill 0049.

Respectfully,



April N. Kapu, DNP, APRN, ACNP-BC, FAANP, FCCM, FAAN  
AANP President